Neumora Therapeutics, Inc.
Neumora Therapeutics, Inc. (Nasdaq: NMRA) is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for brain and centrally mediated diseases. The company operates through a precision neuroscience approach that combines artificial intelligence and machine learning to identify and monitor… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Neumora Therapeutics, Inc. does
In the company’s own words
Neumora Therapeutics, Inc. (Nasdaq: NMRA) is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for brain and centrally mediated diseases. The company operates through a precision neuroscience approach that combines artificial intelligence and machine learning to identify and monitor targeted patient populations, aiming to accelerate drug discovery and improve treatment outcomes relative to traditional development paradigms.
The company's therapeutic pipeline spans three primary disease areas: neuropsychiatric disorders, neurodegenerative diseases, and metabolic disorders. Neumora's most advanced program is navacaprant, a once-daily oral kappa opioid receptor antagonist in Phase 3 development for major depressive disorder, with pivotal studies KOASTAL-2 and KOASTAL-3 fully enrolled. The company is also advancing NMRA-511, a vasopressin 1a receptor antagonist for agitation associated with Alzheimer's disease dementia, which demonstrated clinically meaningful effects in Phase 1b studies. Additional pipeline candidates include NMRA-898, an M4 muscarinic receptor positive allosteric modulator for schizophrenia; NMRA-215, an NLRP3 inhibitor for obesity; NMRA-GCase, a glucocerebrosidase activator for Parkinson's disease; and NMRA-CK1δ, a casein kinase inhibitor for amyotrophic lateral sclerosis.
Neumora's intellectual property portfolio comprises over 400 patents and pending applications across the United States and foreign jurisdictions, including 51 issued U.S. patents and 153 issued foreign patents. The portfolio encompasses molecule patents covering composition of matter and treatment methods, precision neuroscience process patents covering AI and machine learning algorithms, and biomarker patents for patient identification and treatment.
The company has established strategic licensing agreements with leading research institutions and pharmaceutical companies, including exclusive licenses from Amgen for CK1δ and GCase programs, The Scripps Research Institute for KOR and V1aR programs, and Vanderbilt University for M4 receptor programs. These partnerships provide access to validated drug targets and intellectual property while enabling Neumora to focus resources on clinical development and commercialization. More information about Neumora is available at www.neumora.com.
Company details
- Sector
- Healthcare
- Industry
- Biological Products
- Headquarters
- WATERTOWN, MA
- Fiscal year end
- December
- CIK
- 1885522
- SIC
- 2836
Financial performance, year by year
Fiscal 2023–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Neumora Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Neumora Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Neumora Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Neumora Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Neumora Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”